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ABSTRACT 
Background Liver-type fatty acid binding protein (FABP1) has previously been demonstrated to improve prognostic 
discrimination in acetaminophen (APAP)-induced ALF but has not been investigated in other etiologies of ALF. Aim To 
determine whether FABP1 levels (early: admission or late: days 3–5) are associated with 21-day transplant-free survival in 
non-APAP ALF. Methods FABP1 was measured in serum samples from 384 ALF patients (n=88 transplant-free survivors 
(TFS), n=296 died/LT–NTFS) using solid-phase enzyme-linked immunosorbent assay and analyzed with US ALFSG 
registry data. Results Of 384 ALF patients (autoimmune hepatitis n=125, drug-induced liver injury n=141, Hepatitis B 
n=118), 177 (46%) patients received LT. Early FABP1 levels were significantly higher in ALF patients requiring 
vasopressor support (203.4 vs. 76.3 ng/mL) and renal replacement therapy (203.4 vs. 78.8 ng/mL; p<0.001 for both). Late 
FABP1 levels were significantly higher in patients requiring mechanical ventilation (77.5 vs. 53.3 ng/mL), vasopressor 
support (116.4 vs. 53.3 ng/ mL) and in patients with grade 3/4 hepatic encephalopathy (71.4 vs. 51.4 ng/mL; p=0.03 for all). 
Late FABP1 levels were significantly lower in TFS patients (TFS 54 vs. NTFS 66 ng/mL; p =0.049) but not admission (TFS 
96 vs. NTFS 87 ng/ mL; p=0.67). After adjusting for significant covariates, serum FABP1 did not discriminate significantly 
between TFS and patients who died/received LT at day 21 either on admission (p=0.29) or late (days 3–5, p=0.087) time 
points. Conclusion In this first report of FABP1 in non-APAP ALF, FABP1 levels at late time points (days 3–5) were 
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significantly lower in ALF patients who were alive without transplant at day 21 but not after adjusting for covariates 
reflecting severity of illness. Higher FABP1 levels were associated with the presence of increased organ failure. 
Keywords Acute liver failure · Liver-type fatty acid binding protein · Multiorgan failure · Prognosis · ALFSG index 
ABBREVIATIONS 
ALF Acute liver failure 
ALFSG Acute Liver Failure Study Group 
APAP Acetaminophen 
FABP1 Liver-type fatty acid binding protein 
HE Hepatic encephalopathy 
ICU Intensive Care Unit 
INR International normalized ratio 
IQR Interquartile range 
KCC King’s College Criteria 
LT Liver transplantation 
MAP Mean arterial pressure (mm Hg) 
MELD Model for end-stage liver disease score 
MV Mechanical ventilation 
OR Odds ratio 
RRT Renal replacement therapy 
TFS Transplant-free survivor at day 21 
INTRODUCTION 
Acute liver failure (ALF) is defined by the occurrence of encephalopathy and hepatic synthetic dysfunction within 26 weeks 
of the first symptoms of liver disease [1]. In many previous studies, patients have been divided with ALF between those due 
to acetaminophen (APAP) and those with other etiologies since the groups vary greatly in outcomes. Criteria for predicting 
outcome such as the Kings College Criteria (KCC) initially published in 1989 when utilized in further studies have shown 
relatively poor sensitivity of the non-APAP criteria, ranging between 60 and 70% [2]. More recently, the ALFSG prognostic 
index also demonstrated improved accuracy (c-statistic 0.84) but limited sensitivity (37%) in ALF [3].  
Liver transplant (LT) in ALF presents significant challenges due to the rapidity and severity of illness (i.e., high 
risk of cerebral edema and multiorgan failure), the potential for recovery without LT, and the presence of concomitant 
complex psychosocial issues (contraindications) [4]. Given changes in critical care management of ALF, some patients may 
have a good outcome despite meeting poor prognostic criteria and potentially could avoid unnecessary LT in the presence of 
improved prognostic markers or scores [5].  
Fatty acid binding proteins (FABP) are small (<15 kDa) cytoplasmic proteins that are abundantly expressed in 
tissues with active fatty acid metabolism, including hepatocytes. The primary function of FABPs is the intracellular 
transport of long-chain fatty acids [6]. The cellular expression of FABPs is responsive to changes in lipid metabolism, 
which can be induced by pathophysiological conditions, such as ischemia/inflammation [7]. Liver-type FABP (FABP1), 
significantly expressed in hepatocytes, enterocytes, and to a lesser degree in renal tubular cells, has been associated with 
liver injury [6]. Recently, we evaluated the discriminatory ability of FABP1 in 198 APAP ALF patients [8]. Elevated 
FABP1 levels were associated with significantly increased mortality and improved prognostic discrimination when added to 
KCC and the ALFSG prognostic index [8]. However, to date FABP1 has never been evaluated in other causes of ALF.  
This nested case–control study of randomly selected samples from prospectively enrolled patients from the US 
Acute Liver Failure Study Group (ALFSG) registry aimed to examine levels of FABP1 in non-APAP ALF patients. 
Specifically, our primary objectives were to test the following hypotheses:  
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(a) Higher FABP1 serum levels are significantly associated with 21-day transplant-free mortality (in the absence of 
transplant) in non-APAP ALF patients.  
(b) Elevated serum levels of FABP1 in non-APAP ALF are significantly associated with 21-day transplant-free 
mortality after adjusting for other significant covariates.  
METHODS 
STUDY DESIGN 
This study is a nested case–control study of prospectively collected data and biosamples of 384 patients enrolled in the US 
ALFSG registry/biorepository and is outlined in detail in Supplementary File 1. Between January 1998 and December 2016, 
all patients with ALF due to autoimmune hepatitis (AIH, n=125) and Hepatitis B (HBV, n=118) who had serial samples 
available (at least two sample collections from admission and at least 48 h later) were included in this analysis. Of 304 
patients with ALF due to idiosyncratic (non-APAP) drug-induced liver injury (DILI) with serial samples, n=141 patients 
were selected at random by personnel not involved in the analysis of the samples or statistical analysis for the paper. All 
enrolling centers were tertiary academic centers and all but one were liver transplant centers. The authors’ Institutional 
Review Board (IRB)/Health Research Ethics Boards of all enrolling US ALFSG sites have approved all research, and all 
clinical investigation has been conducted according to the principles expressed in the 1975 Declaration of Helsinki. Given 
patients were unable to provide written consent (critical illness, hepatic encephalopathy~HE), written assent was obtained 
from the next of kin from each patient. Each center implemented monitoring and therapeutic interventions according to 
institutional standards of care. Reporting of the analysis of this study followed the STROBE Guidelines for reporting case–
control studies [9]. Consistent with ALFSG studies [3], the primary outcome was 21-day transplant-free survival 
PARTICIPANTS  
Inclusion criteria were (1) evidence of ALF according to the enrollment criteria for the ALFSG (see operational definitions) 
and 2) age ≥18 years; (2) HE during the first seven days of study admission (West Haven Criteria) [10, 11]; and (3) patients 
within the ALFSG registry with primary diagnoses of Hepatitis B (HBV), autoimmune (AIH), and idiosyncratic (non-
APAP) drug-induced liver injury (DILI) determined by the site investigator. Exclusion criteria were: (1) cirrhosis/acute-on-
chronic liver failure and (2) patients with a primary diagnosis of APAP. Serum samples were analyzed on study admission 
early (day 1) and late (either days 3, 4, or 5 where available). Patients who received a LT were included in this study and 
were considered as an unfavorable outcome, in keeping with other previous studies.  
OPERATIONAL DEFINITIONS  
For the purposes of this study, ALF was defined as INR≥1.5 and HE within the first 26 weeks of liver disease in a patient 
with an acute hepatic insult [1]. HE grade was defined by the West Haven Criteria (simplified) as follows: grade 1~any 
alteration in mentation, grade 2 being somnolent or obtunded but easily rousable or presence of asterixis, grade 3 being 
rousable with difficulty, and grade 4: unresponsive to deep pain [10, 11]. In this study, we defined “low coma grade” as 
grade 1 or 2 and “high coma grade” as grade 3 or 4. The KCC [12] predicts poor outcome (death/transplant) if (a) INR is 
greater than 6.5 or three of the following (b) INR is greater than 3.5, bilirubin is greater than 17 mg/dL, age less than 10 or 
greater than 40 years, jaundice for greater than 7 days before development of encephalopathy or unfavorable etiology 
(DILI). The model for end-stage liver disease (MELD) is defined as 10*(0.957*log(4)+0.378*log 
(bilirubin)+1.12*log(INR)) for dialyzed patients and 10* (0.957*log(creatinine)+0.378*log(bilirubin)+1.12*log (INR)) for 
patients not dialyzed [13]. For low coma grade, HE insert 0, and for high coma grade, insert 1. HBV, AIH and DILI are 
defined by the ALFSG index as unfavorable etiologies (insert 0). For the absence of vasopressor use, insert 0, for 
vasopressor use, insert 1.  
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LABORATORY ASSAYS OF FABP1  
FABP1 was measured in serum samples with a solid-phase enzyme-linked immunosorbent assay (ELISA) following 
manufacturer’s instructions (Biomatik, USA). Briefly, samples were incubated 2 h on a monoclonal anti-FABP1 precoated 
plate. A specific FABP1 biotin-conjugated polyclonal antibody solution was added for 2 h. After washing plates, avidin 
conjugated to horseradish peroxidase was added for 30 min. Finally, substrate tetramethylbenzidine was added for 15 min. 
Reactions were stopped by addition of sulfuric acid and absorbance was read at 450 nm. Standard curve ranges from 1.56 to 
200 ng/mL. Samples were performed in duplicate and accepted valid with a variation coefficient less than 25%. The model 
used for the ELISA standard curves was the fourparameter logistic (4-PL) curve fit, with all standard R2 curves superior to 
0.999 using Graph Pad Prism (Sand Diego, USA).  
CLINICAL VARIABLES  
Clinical, biochemical and outcome data were collected prospectively as part of the US ALFSG registry to be analyzed for 
the 384 patients in this study. Data assessed in this study from the registry included demographic (age, race, sex), 
comorbidities, biochemistry early and late (complete blood count, creatinine, transaminases, phosphate, international 
normalized ratio (INR), bilirubin, ammonia, lactate), hepatic coma grade, and requirement for organ support (mechanical 
ventilation (MV), vasopressors, renal replacement therapy (RRT)).  
STATISTICAL METHODS 
For differences between outcome groups (ALF transplant-free survivors, n=88, ALF non-transplant-free survivors, n=296), 
categorical variables were compared using the Chi-squared test or Fisher’s exact test (if n<10 in any cell of the two-bytwo 
table). FABP1 was treated as a continuous variable. Continuous variables were reported as medians with interquartile range 
(IQR) and compared using the Wilcoxon rank sum test. Transplant-free survival was defined as the dichotomous outcome, 
alive or dead/LT at 21 days after enrollment into the registry. A two-sided p value of<0.05 was considered statistically 
significant for all comparisons. In order to control for variables that may confound the effect of FABP1 on 21-day mortality, 
logistic regression analysis was performed [14]. Aside from FABP1, covariates considered in multivariable modeling 
included MELD, lactate, vasopressors use, RRT, MV, and high coma grade. Separate multivariable (logistic) regression 
models were derived for FABP1 early (day 1) and late (days 3–5) by performing backward elimination with a p value 
threshold of 0.05. Model performance was assessed using area under the receiver operating curve (AUROC) and the 
Hosmer–Lemeshow test for goodness of fit. SAS software version 9.4 was used for univariate comparisons and 
multivariable logistic regression modeling.  
RESULTS 
COMPARATIVE ANALYSIS OF 384 ALF PATIENTS 
Demographic and clinical outcomes stratified by transplant-free survival (alive at day 21, n=88; deceased/LT, n=296) are 
shown in Table 1.  
Comparing ALF TFS and deceased/LT at day 21, there were no significant differences in age (45 vs. 47, p=0.39) 
or gender (female; 66% vs. 66%, p=0.93). ALF TFS required significantly less organ support during the 7 days of inpatient 
study (MV: 21% vs. 66% and vasopressors 10% vs. 35%; p<0.0001 for both). ALF TFS patients were less likely to achieve 
high (3 or 4) HE coma grade (30% vs. 73%, p < 0.0001). ALF TFS patients were less likely to require blood products 
during the first 7 days of study including red blood cells (5% vs. 12%, p<0.046), fresh frozen plasma (15% vs. 44%, 
p<0.0001), and platelets (1% vs. 8%, p =0.014). On admission, 46% of ALF TFS and 69% of ALF non-survivors/LT 
patients met KCC (p=0.0001).  
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Table 1 Overall. Demographic and Clinical Parameters in 384 ALF patients stratified by Day 21 outcome. 
N: frequency. IQR: interquartile range.  
CT: computed tomography. CXR; chest x-ray. 
 
Among the 134 ALF non-survivors (irrespective of LT), the most common causes of death reported were 
multiorgan failure (73%) and neurological complications (15%). Cause of death was unknown in 8% of cases.  
Data were stratified by etiology of ALF (AIH, HBV, DILI) and are shown in Supplementary Tables 1, 3, and 5.  
CLINICAL PARAMETERS IN 384 ALF PATIENTS: ADMISSION (EARLY)  
Comparisons of clinical parameters by outcome group on study admission are shown in Table 2. ALF TFS 
survivors had significantly lower serum INR (2.1 vs. 3.2) and bilirubin (16.6 vs. 22.1 mg/dl) compared to ALF LT/non-
survivors (p<0.0001 for all comparisons). Transplant-free survivors also demonstrated significantly lower MELD scores (20 
vs. 27, p<0.0001) than ALF LT/non-survivors on admission. On study admission, survivors were significantly less likely to 
be mechanically ventilated (14% vs. 43%, p<0.0001) or achieve high HE grade (21% vs. 48%, p<0.0001).  
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Admission (early) levels of FABP1 are shown in Table 2 and graphically in Fig. 1. There were no statistically 
significant differences in FABP1 levels between ALF TFS (96.3 vs. 87.2 ng/mL) and ALF patients that died/required LT 
(p=0.67). Data stratified by etiology of ALF (AIH, HBV, and DILI) are shown in Supplementary Tables 2, 4, and 6.  
CLINICAL PARAMETERS IN 328 ALF PATIENTS: DAY 3–5 (LATE)  
Comparisons of clinical parameters by outcome group on days 3–5 (late) are shown in Table 2. Of the 88 ALF 
TFS, 78 patients had data available at a late time point. Of the 296 ALF patients who died/required LT, 250 patients had 
data at a late time point. At late time points, ALF TFS patients (n = 78) had significantly lower serum INR (2.0 vs. 2.8), 
bilirubin (17.3 vs. 20.6 mg/dl), and lactate levels (2.2 vs. 4.7 mmol/L) compared to ALF non-survivors/LT recipients 
(n=250; p<0.02 for all comparisons). ALF TFS patients also demonstrated significantly lower late MELD scores (19 vs. 27, 
p<0.0001) than non-survivors. At late time points, ALF TFS patients were significantly less likely to be on mechanical 
ventilation (15% vs. 51%) and vasopressors (4% vs. 23%) or achieve high HE grade (20% vs. 56%, p<0.0001 for all 
comparisons).  
Late (days 3–5) levels of FABP1 are shown in Table 2 and graphically in Fig. 1. ALF TFS patients had 
significantly lower late serum FABP1 levels (53.8 vs. 65.6 ng/mL) compared with ALF non-survivors/LT recipients 
(p=0.049). Data stratified by etiology of ALF (AIH, HBV, and DILI) are shown in Supplementary Tables 2, 4, and 6.  
CORRELATION BETWEEN FABP1 LEVELS AND ORGAN DYSFUNCTION/REQUIREMENT FOR SUPPORT 
 ALF patients were stratified based on requirements for organ support in Table 3. At early time points, serum 
FABP1 levels were significantly higher in ALF patients requiring vasopressor support (203.4 vs. 76.3 ng/mL) and renal 
replacement therapy (203.4 vs. 78.8 ng/mL; p<0.001 for both). At late time points, serum FABP1 levels were significantly 
higher in ALF patients requiring mechanical ventilation (77.5 vs. 53.3 ng/mL, p = 0.006), vasopressor support (116.4 vs. 
53.3 ng/mL; p<0.001) and in ALF patients with high-grade hepatic encephalopathy (grade 3 or 4; 71.4 vs. 51.4 ng/mL; 
p=0.03).  
MULTIVARIABLE ANALYSIS: ASSOCIATIONS WITH 21DAY MORTALITY 
 In order to adjust for covariates, multivariable logistic regression for 384 ALF patients to determine associations 
(adjusted) with 21-day mortality was performed (Table 3). Two models were derived; one on admission (early) and one at 
days 3–5 (late). Values of serum FABP1 were transformed to their natural logarithm (log FABP1) to comply with the 
linearity assumption in logistic regression.  
EARLY (ADMISSION) MODEL  
After adjusting for covariates, the multivariable early model included requirement for high coma grade (odds ratio 
OR 3.97, 95% CI (2.01–7.85), p<0.0019), log (INR) (OR 5.38 (2.75, 10.53), p<0.0001) and bilirubin (OR 1.10 (1.06, 1.14) 
per increment, p<0.0001), and etiology of ALF (p=0.27). Log (FABP1) (OR 1.13 (0.90–1.40) per unit, p=0.29) was not 
independently associated with death/LT after adjusting for other covariates. This model demonstrated AUROC of 0.82. 
While etiology of ALF was not statistically significant (p=0.27), early multivariable models stratified by etiology of ALF 
(AIH, HBV, and DILI) are shown in Supplementary Tables 7, 8, and 9.  
LATE (DAYS 3–5)  
Model After adjusting for covariates, the multivariable late (days 3–5) model included MELD (OR 1.09 (1.05–
1.14) per increment, p<0.0001) and etiology of ALF (p=0.67). Log  (FABP1) (OR 1.27 (0.97–1.68) per unit, p = 0.087) was 
not independently associated with death/LT after adjusting for other covariates. This model demonstrated AUROC of 0.76. 
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While etiology of ALF was not statistically significant (p = 0.67), late multivariable models stratified by etiology of ALF 
(AIH, HBV, and DILI) are shown in Supplementary Tables 7, 8, and 9. 
A comparison of model performance (AUROC) for KCC, MELD, and the ALFSG prognostic index alone and with 
the addition of FABP1 is shown in Supplementary Table 10. Addition of FABP1 to KCC or MELD was not significant for 
early or late time points, nor was it significant when added to ALFSG PI for early time points; however, for late measures 
(days 3–7), addition of FABP1 to the ALFSG PI resulted in significant improvement in AUROC (p=0.027).  
Table 2  Overall. Biochemical and organ support parameters early (admission) and late (day 3–5) stratified 21-day 
outcome  
N, frequency; IQR, interquartile range; INR, international normalized ratio; ALT, alanine aminotransferase; and MELD, 
model for end-stage liver disease 
a Hepatic encephalopathy grade according to West Haven Criteria 
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Fig. 1  Serum levels of FABP1 (ng/mL) in healthy controls, transplant-free survivors (TFS) (early 
admission), patients who died/required LT (NTFS, early), TFS (late ~ day 3–5), NTFS (late) 
 
 
Table 3  FABP1 median (IQR) for early and late samples by clinical descriptors 
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DISCUSSION 
KEY RESULTS 
In this nested cohort study of 384 ALF patients, we report the first published analysis of FABP1 in a large series of well-
characterized ALF patients due to AIH, HBV, and idiosyncratic DILI. Serum levels of FABP1 were significantly lower at 
late time points (days 3–5) in ALF TFS at day 21. However, after adjusting for significant covariates reflecting severity of 
illness (MELD), serum FABP1 (log) levels were not significantly associated with 21-day mortality measured either at early 
(OR 1.13, p = 0.29) or late (OR 1.27, p = 0.087) time points (Table 4).  
Table 4  Overall. Early (day 1) and Late (days 3–5) predictors of 21-day mortality in 384 ALF patients 
COMPARISON WITH LITERATURE  
ALF represents the severest form of hepatic injury resulting from massive necrosis. In the presence of hepatocyte injury, 
cytoplasmic proteins pass through large clefts embedded within a single endothelial cell layer and into the circulation. 
Hepatocyte damage results in FABP1 detection in blood [15] and has been proposed as a sensitive serum marker of 
hepatocellular damage in liver transplant recipients [16]. FABP1 has theoretical physiological properties that could 
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potentially be advantageous as a prognostic biomarker. It is present in high abundance in hepatocytes (approximately 2.7 
mg/g of liver tissue), has a lower molecular mass (14 kDa) and shorter plasma half-life (11 min) compared to other cytosolic 
proteins (e.g., ALT) [17]. Due to its low molecular mass, FABP1 levels in the serum are influenced by both renal function 
and RRT. FABP1 is present in significantly smaller quantities in the kidney (proximal tubules) [18, 19].  
FABP1 has previously been shown to be a diagnostic marker of liver injury in patients with DILI in the absence of 
ALF [20]. Recently, we evaluated the discriminatory ability of FABP1 in 198 acetaminophen (APAP)-ALF patients [8]. 
Elevated FABP1 levels were associated with increased mortality and improved prognostic discrimination when added to 
KCC and the ALFSG prognostic index [8]. In contrast, FABP1 did not appear to be as discriminatory between favorable 
(transplant-free survival) and unfavorable outcomes (death, requirement for LT) in other etiologies of ALF such as 
autoimmune, Hepatitis B, and DILI after adjusting for other covariates. One possible reason for this is that acetaminophen 
hepatotoxicity is characterized by hyperacute liver failure with the rapid (within 7 days usually) progression from onset of 
synthetic dysfunction to the development of ALF. Hence, there is likely a massive amount of hepatocyte necrosis occurring 
in a relatively short period of time [1]. In contrast to this, other causes of ALF such as autoimmune hepatitis, DILI, and 
Hepatitis B can follow a more subacute time course where the development of hepatocyte necrosis occurs over many days 
or weeks prior to the development of hepatic encephalopathy. This is further supported by a recent study by Eguchi and 
colleagues, which demonstrated median FABP1 levels of between 9 and 15 ng/mL in cirrhosis patients (i.e., minimal 
necrosis) with hepatocellular carcinoma, significantly lower that what were demonstrated in this study of non-APAP ALF 
[21].  
FABP1 is involved in uptake, transport, and metabolism of long-chain fatty acids and has multiple biologic 
functions (fatty acid transport, storage, and metabolism) [22]. FABP1 also has an important role in facilitating hepatic fatty 
acid oxidation and is involved in trafficking and delivery of various ligands to cellular destinations such as enzymes, 
membranes, and nucleus [23]. FABP1 also acts as a cellular antioxidant as it contains a cysteine group and has been found 
to influence cell growth, since it has been demonstrated to be elevated during stages of mitosis [24]. Hepatic longchain fatty 
acid uptake is directly associated with FABP1 expression levels [25]. Therefore, an increased expression of hepatocyte 
FABP1 could be a compensatory mechanism in attempt to rescue energy-deprived hepatocytes undergoing necrosis. A 
failed attempt elicits necrosis, resulting in upregulated levels of FABP1 being released into circulation. Therefore, we 
speculate that while rapid massive necrosis of hepatocytes containing overexpressed levels of FABP1 could justify the 
association with non-spontaneous hepatic recovery in acetaminophen hepatotoxicity, due to the temporal relationship of 
hepatocyte necrosis in subacute liver failure (DILI, HBV, autoimmune), FABP1 was less discriminatory between favorable 
and unfavorable outcomes in these patient populations. This dichotomy is also reflected in ALF prognostic scores including 
the King’s College Criteria (APAP vs. non-APAP) [12] and the ALFSG prognostic index (etiology subclasses) [3].  
LIMITATIONS  
The following limitations of this study warrant consideration. It is a nested case control study, and as such the event rate of 
the primary outcome (death or liver transplant at 21 days) was 75%, higher than published in cohort series. Although 
patients were enrolled and samples were collected prospectively, analysis was done retrospectively and therefore can 
comment on association and discrimination (between transplant-free survivors and non-survivors/LT patients) and not on 
the absolute risks of death according to serum FABP1 levels. To account for potential confounding in the study design, we 
performed multivariable analysis to adjust for other significant covariates. The case–control design of the study may have 
introduced selection bias, as the primary outcome of transplant-free survival is automatically unbalanced within the clinical 
profile of the groups. However, in an attempt to reduce observation bias, data were collected prospectively and within this 
specific study design, researchers measuring FABP1 were blinded to the clinical and outcome data of patients at the time of 
patient selection and sample analysis. We did not have access to a control group with critical illness but not APAP ALF or 
acute-on-chronic liver failure as comparators; however, we did include a control group of healthy adults for comparison. 
Indeterminate/seronegative ALF patients were not included in this analysis due to ongoing causality reclassification at the 
time of sample pull. Further studies evaluating other markers related to the FABP pathway would be of value; however, we 
were unable to perform due to limitations in sample volume. Nonetheless despite these limitations, we believe these results 
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are robust as they include 384 ALF cases from across 16 tertiary liver transplant centers comprising the US ALFSG. 
Furthermore, this builds on the body of evidence that suggests the differences in the natural history of hepatocyte injury in 
hyperacute liver failure (acetaminophen toxicity), acute/subacute liver failure (this study), and cirrhosis reflected by levels 
of FABP1.  
CONCLUSION  
In this first report of FABP1 in non-APAP ALF, FABP1 levels at late time points (day 3–5) were significantly lower in 
ALF patients who were alive without transplant at day 21 but not after adjusting for other covariates. Higher FABP1 levels 
were associated with the presence of increased organ failure.  
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